New hope for myasthenia crisis: early ravulizumab may speed ICU recovery
NCT ID NCT07411963
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether giving the drug ravulizumab early, right after standard crisis treatments like plasma exchange or IVIg, can help people with severe myasthenia gravis recover faster in the ICU. About 30 adults with a specific antibody type will be followed for 6 months. The goal is to see if this approach shortens time on a ventilator, reduces hospital stay, and improves muscle strength.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ravulizumab (Ultomiris)
What this could lead to
If early ravulizumab helps patients recover faster from a myasthenic crisis, it could shorten ICU stays and reduce complications, improving care for this rare condition.
What could go wrong
This is a small observational study (30 patients) with no control group, so results may not prove cause and effect. Ravulizumab is already approved for maintenance, but its early use in crisis is not yet validated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de NICE
RECRUITINGNice, Alpes-maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••